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Biomarkers can help unravel mechanisms of disease and identify new targets for therapy.
They can also be useful in clinical practice for monitoring disease progression, evaluation of
treatment efficacy, and risk assessment in multifactorial diseases, such as age-related macular
degeneration (AMD). AMD is a highly prevalent progressive retinal disorder for which multiple
genetic and environmental risk factors have been described, but the exact etiology is not yet
fully understood. Many compounds have been evaluated for their association with AMD. We
performed an extensive literature review of all compounds measured in serum, plasma, vit-
reous, aqueous humor, and urine of AMD patients. Over 3600 articles were screened, resulting
in more than 100 different compounds analyzed in AMD studies, involved in neo-
vascularization, immunity, lipid metabolism, extracellular matrix, oxidative stress, diet, hor-
mones, and comorbidities (such as kidney disease). For each compound, we provide a short
description of its function and discuss the results of the studies in relation to its usefulness as
AMD biomarker. In addition, biomarkers identified by hypothesis-free techniques, includinghD, Department of Ophthalmology, Radboud University Medical Center, Philips van Ley-
nds.
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s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 12metabolomics, proteomics, and epigenomics, are covered. In summary, compounds belonging
to the oxidative stress pathway, the complement system, and lipid metabolism are the most
promising biomarker candidates for AMD. We hope that this comprehensive survey of the
literature on systemic and ocular fluid compounds as potential biomarkers in AMDwill provide
a stepping stone for future research and possible implementation in clinical practice.
ª 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction understanding the genetic architecture of AMD, the exactThe term biomarker refers to an objective, measurable
characteristic that is indicative of a biological process (normal,
pathogenic, or in response to treatment).30 Biomarkers can
help unravel mechanisms of disease and identify (new)
targets for treatment. The potential benefit of biomarkers in
drug development is to allow earlier, more robust drug safety
and efficacy measurements.385 In addition, biomarkers can be
useful in clinical practice for detecting disease, monitoring
disease progression, evaluation of treatment efficacy, and risk
assessment. Biomarker testing is an important step toward
personalized medicine in many diseases, such as cancer,198
but also in age-related macular degeneration (AMD).
AMD is the leading cause of irreversible loss of vision
among the elderly in theWesternworld, and the prevalence of
AMD is expected to increase with population ageing.364
The early stage of AMD is characterized by subretinal
yellowish deposits, known as drusen, and changes inmacular
pigmentation.43,151 At this stage, patients usually express little
or no complaints. As AMD progresses, central vision becomes
increasingly blurred, resulting in irreversible vision loss in the
advanced stages of the disease. Two subtypes of advanced
AMD can be distinguished: geographic atrophy (GA) and
neovascular AMD (nAMD).43,151 The atrophic form of AMD is
characterized by cell death of the retinal pigment epithelium
(RPE) and photoreceptors causing gradual vision loss.136 Neo-
vascular AMD, also referred to as “wet” or “exudative” AMD, is
characterized by abnormal vessel growth into the retina from
the choroid (choroidal neovascularization [CNV]). Leakage
from these fragile neovascularizations can cause rapid loss of
vision.363 In this review, we will use the following terms for
the different AMD subgroups described in literature: any AMD,
early AMD, advanced AMD (GA/neovascular/any advanced),
and dry AMD (for definitions of these terms, see Table 1).
AMD is a multifactorial disease, and many risk factors for
the development of AMD have been described. The most
commonly reported environmental risk factors include aging,
smoking, family history, low dietary intake of antioxidants
and omega-3 fatty acids, and reduced physical activ-
ity.44,192,204 In addition,multiple genetic risk factors have been
identified, consisting of genetic variants that are either com-
mon or rare in the population. A large risk effect has been
reported for genetic variants located at the CFH and ARMS2/
HTRA1 loci.101 Most genes associated with AMD can be clus-
tered into 5 main pathways: the complement pathway, lipid
transport, extracellular matrix (ECM) remodeling, angiogen-
esis, and cell survival.100 Despite considerable progress indisease etiology is not yet fully understood.
In attempts to unravel the etiology of AMD, to improve
patient stratification, to monitor disease progression, and to
discover new drug targets, many biomarker studies have been
performed. In general, new analytical strategies have
emerged, moving from single markers toward complex
biomarker signatures, increasing the chance for greater
specificity and a higher diagnostic or predictive value.
There has been no comprehensive overview of all potential
biomarkers and their applicability in AMD. Here, we present a
detailed summary of the current literature on molecular com-
pounds reported as analyzed in serum, plasma, aqueous humor,
vitreous, and urine of AMD patients. The scope of this review is
limited to nongenetic chemical compounds. For all compounds,
a short description of their function is provided, and the results
of the studies are summarized anddiscussed in relation to AMD.
Currently, most of these markers are not yet established as
routine clinical diagnostic tools and are discussed here to direct
future research and eventually clinical implementation.2. Neovascularization and hemostasis
Because choroidal neovascularization is one of the subtypes of
advanced AMD, it is not surprising that the factors involved in
neovascularization and hemostasis have been extensively
studied. The results of the studies describing these factors are
described in Sections 2.1 and 2.2, respectively. A complete
overview of the studies and references is provided in Sup-
plementary Table 1.
2.1. Neovascularization
2.1.1. Vascular endothelial growth factor and soluble VEGF
receptor 1
Vascular endothelial growth factor (VEGF) is currently the
most important target in the treatment of nAMD, and the
expression profile of VEGF has been extensively investigated
in AMD patients. VEGF acts as a hypoxia-driven local signal to
induce the formation of new blood vessels. Treatments
inhibiting its function can partially restore and/or maintain
vision in nAMD patients.
Contrary to expectation, VEGF is not consistently upregu-
lated in AMD patients across studies. One study showed that
VEGF levels in the aqueous humor of 12 nAMD patients were
highly elevated (668.9 pg/mL) compared with 10 controls
(cataract patients; 108.3 pg/mL).334 In a second study involving
Table 1 e Explanation of terms used in this review to describe different types of AMD
Type of AMD Criteria
Any AMD No specific definition of AMD reported or analyses were performed on all AMD stages together
Early AMD Analyses were performed on AMD cases in the absence of advanced stage disease (GA or CNV) and
can include early and/or intermediate AMD
Advanced: GA Geographic atrophy of the RPE secondary to AMD
Advanced: neovascular Choroidal neovascular lesion (active or occult) secondary to AMD, including serous and/or hemorrhagic
RPE detachment, subretinal fibrovascular tissue and scarring
Any advanced AMD No specific definition of advanced AMD reported or analyses were performed on both advanced AMD
stages (GA and CNV) together
Dry AMD No specific definition of dry AMD reported or analyses were performed on AMD cases in the absence of
advanced neovascular AMD (can therefore include early AMD and/or advanced: GA)
AMD, age-related macular degeneration; CNV, choroidal neovascularization; GA, geographic atrophy; RPE, retinal pigment epithelium.
s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 1 3aqueous humor, however, significant higher VEGF levels could
only be demonstrated in the most aggressive form of nAMD
(type 3 neovascularization) compared with controls.74 A third
study did not report a difference in VEGF levels in aqueous
humor between nAMD and controls at all.290 Of note, a
considerable range in VEGF levels in aqueous humor exists
among these studies. In the study by Tong and colleagues,334
the levels of VEGF in control individuals were around 100 pg/
mL, whereas the VEGF levels in the 2 other studies were much
lower in controls (39.5 pg/mL and 63.9 pg/mL, respec-
tively).74,290 These differencesmay be explained by the use of 3
different analytical systems, emphasizing the need for stan-
dardized assay systems for key marker compounds in eye
fluids. In addition, studies analyzing VEGF levels in vitreous
samples did not detect differences between VEGF levels of
nAMD cases and controls.135,142
Although the measurement of VEGF levels in vitreous or
aqueous humor is expected to best reflect VEGF levels in the
macula, the procedure is invasive and therefore not desirable in
individuals with early or intermediate AMD. Thus, for purposes
of a clinical tool for diagnosis and progression,measurement of
VEGF levels in more accessible body fluids such as serum or
plasma is preferable. Several studies did investigate VEGF levels
in AMD patients and controls in serum or plasma, with mixed
results. Four studies detected significantly upregulated levels of
VEGF in serum or plasma,6,115,205,338 but these findings are
contrasted with 10 other studies that reported no
association.41,80,112,122,125,211,231,299,353,380
VEGF signaling is mediated through a complex of receptors
and coreceptors, of which the soluble form of VEGF receptor 1
has been investigated in a number of studies. As in the case of
VEGF, these studies do not offer a clear direction of effect. One
study investigated the levels of soluble form of VEGF receptor
in vitreous and found that levels were higher in nAMD
patients.142 In contrast, 2 studies performed on serum could
not corroborate these findings. One of the studies did not find
any association,256 the other even reported lower levels of
soluble form of VEGF receptor in nAMD.340
2.1.2. Pigment epitheliumederived factor
Pigment epitheliumederived factor (PEDF) is produced by RPE
cells and has antiangiogenic properties, opposing the effects
of VEGF. It has been proposed as a target to inhibit choroidal
neovascularization and its expression signature in modelsystems suggests that it is downregulated under hypoxic
conditions.139 Two studies on vitreous support this by
demonstrating a marked reduction in PEDF levels in AMD
patients versus controls.135,142 One study analyzing aqueous
humor showed the opposite result, an increase of PEDF levels
in AMD patients.334 These conflicting results are not readily
explained. It is possible that in different fluids or in different
parts of the eye (anterior/posterior), PEDF is regulated differ-
ently, but additional experiments are needed to determine the
direction of the effect with certainty.
2.1.3. Transforming growth factor beta
Transforming growth factor beta (TGF-b) has been described to
increase the expression of VEGF and is therefore also impli-
cated in neovascularization.20 In vitreous samples of nAMD
patients, TGF-bwas significantly elevatedwhen comparedwith
controls (patients with idiopathic macular holes).20 An earlier
study had already demonstrated that urinary TGF-b levels were
increased in cases compared with controls, but only in early
AMD was the difference significant.1212.2. Hemostatic system
2.2.1. Fibrinogen
Fibrinogen is a hemorheological factor involved in endothelial
functioning.34 Abnormalities in this factor are linked to
thrombogenesis and vascular disorders166; hence, fibrinogen
has been examined for its potential involvement in AMD.
Studies have yielded mixed results. A number showed that
increased fibrinogen level is a significant risk fac-
tor,65,205,223,271,321 whereas others did not find evidence for an
association.58,149,185,188,288,295,331,352,367
2.2.2. Plasminogen activator inhibitor 1
Plasminogen activator inhibitor 1 is another main component of
the fibrinolytic system.29 Four studies have investigatedwhether
a relation between plasminogen activator inhibitor 1 and AMD
exists, with some support for a positive association,367 whereas
other studies did not find any association.26,288,352
2.2.3. Platelet count
Several studies have measured platelet count. Most did not find
any association between platelet counts andAMD.149,180,181,186,205
s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 14Two larger studies did find lower platelet counts inAMD, but this
minimally protective effect for platelets on the development of
AMD was only significant in univariate analyses.50,285
2.2.4. Von Willebrand factor
Von Willebrand factor is a blood glycoprotein that is essential
for normal hemostasis.289 Because vascular pathology is hy-
pothesized to be involved in the pathogenesis of AMD, Von
Willebrand factorwas investigated as a possible risk factor. One
study showed higher levels compared with controls (but in
multivariate analysis no significant correlation was found),205
and 3 more studies found no association at all.288,352,367
In summary,many inconsistent results for factors involved
in neovascularization have been reported, and further work is
required to determine whether these could be used as AMD
biomarkers. Factors involved in hemostasis described in Sec-
tion 2.2 are unlikely to serve as biomarkers for AMD.Uptake
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The human body is dependent on an aerobic environment for
survival. This constant exposure to oxygen can lead to detri-
mental oxidative modifications of cell components and tis-
sues. Usually, cells are equipped with sufficient antioxidative
mechanisms to maintain oxidant homeostasis, but if this
balance is disrupted, oxidative stress occurs.38 Oxidative
stress in cells and tissues is characterized by an excess in
molecules containing free radicals such as reactive oxygen
species (ROS) and reactive nitrogen species.
Polyunsaturated fatty acid (PUFA) molecules are present in
lipids on the membranes of cells and are prone to oxidation
due to the presence of susceptible double carbon bonds.38,245
During the process of lipid peroxidation by ROS, the double
carbon bond is oxidized, leading to the formation of unstableApoA1
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[MDA]).18,22,263,357 ROS can also oxidize proteins, resulting in 2-
(u-carboxyethyl) pyrrole (CEP) protein adducts117 and induce
formation of advanced glycosylation end products (e.g.,
Nε-carboxymethyllysine).146,304
Increased oxidative stress is thought to be one of the un-
derlying factors in the occurrence of AMD.18,24,38,245,333,374 The
eye, and especially the macula, is susceptible to oxidative
stress because of its high metabolic activity and high PUFA
content in the membranes of the photoreceptors.38 High ox-
ygen pressure from the blood in the choroid and exposure to
bright light also causes increased ROS levels in the
retina.22,263,333 In addition, photoreceptors are subjected to
constant shedding, and subsequent phagocytosis of the shed
fragments leads to ROS generation.38,374 Environmental
factors such as smoking and alcohol consumption can also
increase ROS production.346 Therefore, factors related to
oxidative stress could potentially be valuable biomarkers for
the incidence and/or progression of AMD and are discussed in
more detail in Sections 3.1e3.4. A schematic overview of these
oxidative stress related factors is provided in Fig. 1 and a
complete overview of the studies and references is provided in
Supplementary Table 2.3.1. Oxidation products
3.1.1. Malondialdehyde
MDA is one of the reactive carbonyl compounds originating from
PUFA oxidation, and its presence is often used to measure lipid
peroxidation levels in blood or serum samples.18,22,335 Increased
systemic levels of MDA have been consistently observed in both
wet and dry AMD.18,22,86,155,263,311,335,336,346,374,375 In addition, an
allele-dependent increase of MDA levels was measured in
subjects carrying the A69S variant (rs10490924) in the ARMS2
gene that is associated with AMD. Patients heterozygous or
homozygous for the risk allele showed higher MDA levels.263
MDA is a highly reactivemolecule that forms covalent bonds
with the amino acids of endogenous proteins. This MDA modi-
fication can be recognized by factors of the innate immune
system such as complement factor H (FH), immunoglobulin M
(IgM), and macrophages.53,357,358 Binding of MDA by IgM or
macrophages leads to a proinflammatory response by
increasing the expression of the inflammation factor interleukin
(IL)-8,274,358 whereas binding to FH attenuates inflammation.358
3.1.2. CEP adducts and N(6)-carboxymethyllysine (CML)
Docosahexaenoic acid (DHA) accounts for about 80% of all
PUFAs in the photoreceptor outer segments and is most prone
to oxidation in human tissues.96 Upon oxidative stress, DHA is
oxidized forming specific CEP adducts.117 Plasma CEP levels in
AMD patients are elevated compared with controls.118,242,351
Moreover, elevated CEP levels combined with AMD risk
alleles in ARMS2, HTRA1, CFH, or C3 increased the risk of AMD
twofold to threefold compared with genotype alone.118
Furthermore, plasma of AMD patients containedmore and
a higher diversity of CEP autoantibodies compared with
controls in 2 studies from the same group.117,118 Another
independent study found no association between CEP auto-
antibodies and AMD.242CML is an advanced glycation end product that originates
from a protein lysine modification and is a major immuno-
logical epitope recognized by the immune system.146 Plasma
CML levels were upregulated in AMD in one study,242 but no
significant difference was found in another.304
Both CEP adducts and CML are present on proteins. They
are recognized by the immune system146,359 and can stimulate
angiogenesis in vivo.78,248 Receptor-mediated binding of CEP
adducts results in an angiogenic response of endothelial cells
independent of VEGF signaling.359 Upregulation of CML and
CEP levels in AMD might be implicated in the progression to-
ward nAMD by promoting angiogenesis, but further studies
are necessary to support this hypothesis.
3.1.3. Protein carbonyl groups and total oxidation status
Levels of protein carbonyl groups are often used to assess the
total protein oxidation status in subjects as they are easy to
measure.64 Protein carbonyl groups consist of an oxygen
molecule bound to a carbon atomwith a double bond (-RC¼O)
resulting from protein oxidation and are therefore indicative
of oxidative stress. Elevated levels of both protein carbonyl
group336,379 and total oxidation status336,341 were found in
nAMD patients.
3.1.4. Oxidized low density lipoprotein
Low-density lipoprotein (LDL) is abundantly present in and
around cells and is an easy target for oxidation by ROS. LDL
cholesterol (LDL-C) has been studied extensively in the
context of AMD, described in Section 5.2; however, studies on
its oxidized form (oxidized low density lipoprotein [Ox-LDL])
are more limited. Higher Ox-LDL levels were found systemi-
cally in AMD patients compared with controls,147,152,153 but a
lack of association has also been reported.184
Increased Ox-LDL levels are known to activate various
factors of the complement system such as C3b, C5b-9, and
complement factor B (FB).79 These factors are described inmore
detail in Section 4.1. High Ox-LDL levels as observed in AMD
might initiate apoptosis of RPE cells through disruption of the
mitochondrial pro- (Bax) and antiapoptotic (Bcl2) balance,373
leading to GA. In addition, uptake of Ox-LDL molecules by
macrophages contributes to the formation of foam cells,
implicated in the development of atherosclerotic plaques.270
3.2. Nitric oxide
Nitric oxide is one of the most abundant free radicals in the
human body and is able to react with other ROS resulting in
cell dysfunction and apoptosis.86 It is synthesized by endo-
thelial cells and is an important vasoactive agent affecting
blood flow and other vascular functions.28 Involvement of
nitric oxide in AMD is less clear. One study observed increased
levels of nitric oxide in AMD patients,86 another study
described downregulation of nitric oxide in nAMD,335 and a
third study reported no association.338
3.3. Homocysteine
Homocysteine is an intermediatemolecule in the conversion of
the amino acidmethionine to cysteine and glutathione (GSH), a
process mediated by multiple enzymes.104,294 Homocysteine
s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 16can autooxidize in plasma, leading to the formation of various
reactive products such as homocysteine thiolactone, which is
also accompanied by ROS generation (Fig. 1).60
Dysregulation of the homocysteine balance has been
associated with various diseases such as vascular dysfunc-
tion, autoimmune diseases, and neurodegenerative disor-
ders.294 Increased systemic levels of homocysteine were
observed in both neovascular and dry forms of AMDcompared
with controls,18,19,60,110,113,152,153,168,213,284,300,347 and there
were also higher levels in the vitreous of nAMD patients.213
Moreover, some studies found higher homocysteine levels in
nAMD compared with dry AMD19,110; however, other studies
did not find an association between homocysteine levels and
AMD.54,132,188,247,352,3673.4. Antioxidants
Antioxidants enhance ROS clearance and prevent ROS forma-
tion thereby averting damage in the aging eye and other
tissues.333 Enzymes such as catalase, superoxide dismutase,
and paraoxonase prevent the accumulation of oxidized lipids
by converting ROS before they can react or by removing the
oxidized products from the endogenous proteins.333 Several
vitamins and trace elements act as cofactors for these
enzymes, or react with ROS to prevent accumulation.357,374
Multiple studies hypothesized that the antioxidant capacity
in AMD patients might be impaired, and some showed a
decreased overall antioxidant capacity in serum of pa-
tients.58,87,269,311,336,379 In the following sections,wediscuss levels
of thiols (Section 3.4.1), carotenoids (Section 3.4.2), and enzymes
with antioxidant activity (Section 3.4.3) in AMD patients.
3.4.1. Thiols and GSH
Thiols mediate an important part of the balance between
proper oxidation versus antioxidants in tissues. Their main
characteristic is a carbon-bonded sulfhydryl group (C-SH),
which can form a disulfide bridge with other thiols via redox
reactions (C-S-S-C). Thiols can neutralize ROS by providing an
electron during the formation of the disulfide bridge.218
Although their normal function is to prevent oxidative
stress, thiols can also promote oxidative stress in the presence
of metal ions such as iron.152
Thiol content is either measured by focusing on the indi-
vidual thiols or by evaluating total thiol (tSH) content of the
blood. GSH is one of the most important thiols in the body.
GSH can be transformed into glutathione disulfide (GS-SG) by
the enzyme glutathione peroxidase (GSHP), thereby breaking
down hydrogen peroxide (2 GSH þ H2O2/ GS-SG þ 2 H2O).218
Glutathione reductase (GSHR) is able to transform the formed
glutathione disulfide to its monomeric form (GS-SG þ NADPH
þHþ/ 2 GSHþNADPþ), making it available for conversion by
GSHP again.218 This circular process (Fig. 1) is of vital impor-
tance for proper ROS maintenance.
Lower levels of GSH and tSH are thought to result in more
ROS formation owing to the absence of hydrogen peroxide
clearance, resulting in subsequent oxidative damage.60,333 Lower
levels of total thiol content60,152,341 and plasma GSH60,152 were
found in patients with AMD compared with control subjects,
and bothwere negatively correlatedwith homocysteine levels60;however, multiple studies have found no association between
systemic GSH levels and AMD.35,72,273,291,375
Plasma and serum GSHR levels were lowered in patients
with AMD,55,58,379 although 1 study did not find this associa-
tion in erythrocytes.68 Systemic GSHP levels were lowered in
some studies85,269,272,346 and higher in 1 study,71 but in most
studies, no association was found.55,58,68,375,379
3.4.2. Carotenoids
Carotenoids are a group of natural red and yellow hued pig-
ments (carotenes and xanthophylls) synthesized in most
plants. The antioxidant capacity of carotenoids is based on
their ability to absorb and process free electrons from ROS
such as singlet oxygen (1O2) and peroxyl radicals (ROO
). After
the uptake of an electron, the carotenoid releases its energy in
the form of heat and can be used again. Humans are unable to
synthesize carotenoids and rely on dietary intake of vegeta-
bles.95,325 In AMD, total serum carotenoid levels were
decreased in 2 studies by the same group,87,88 whereas 2 other
studies described a lack of association.40,313
Twomain xanthophylls are located in themacula: lutein is
concentrated in the peripheral macula and zeaxanthin in the
fovea. Here, they are able to attenuate blue light wavelengths,
preventing the light from reaching and damaging the under-
lying photoreceptors.195 In blood, lutein and zeaxanthin are
transported by lipoproteins such as high-density lipopotein
(HDL) and LDL. Zeaxanthin and lutein exert their antioxidant
abilities by reacting with free radicals both in the macula and
in blood.195 Levels of lutein and zeaxanthin were found to be
decreased in AMD patients in several studies.70,87,384 One
study described decreased levels of zeaxanthin but not lutein
in AMD patients.103 Others found no association for either
lutein or zeaxanthin.40,214,224,292,313
b-cryptoxanthin is a carotenoid most commonly found in
citrus fruits. Besides its role as an antioxidant, in vitro ex-
periments have shown that b-cryptoxanthin also stimulates
DNA repair mechanisms.206 Levels of b-cryptoxanthin were
decreased in patients with advanced AMD in some
studies,87,224,313,384 whereas others did not find a significant
association with AMD.40,70,214,292
A decrease of a-carotene was found in patients with
nAMD,87,384 whereas higher levels of a-carotene were present
in early AMD.384 Also b-carotene levels were decreased in
advanced AMD in some studies87,224,384; however, most
studies did not find a significant association between AMD
and a-carotene or b-carotene levels.40,70,214,224,292,313,322,360
Importantly, supplementation of b-carotene has been associ-
ated with an increased risk of lung cancer in smokers and
former smokers, and therefore, long-term use to inhibit AMD
progression is not recommended.5,251
Finally, one of the most potent antioxidants present in
blood is lycopene. The main dietary sources of this red
pigment carotenoid are red fruits or vegetables, such as to-
matoes.102 Levels of lycopene were either decreased in AMD
patients40,313,384 or not associated with AMD.70,87,214,224,292
In summary, when studies reported a significant associa-
tion between carotenoids and AMD, the vast majority
described decreased carotenoid levels in patients. This prob-
ably reflects a difference in dietary intake of these carotenoids
between AMD patients and controls. Several studies reported
s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 1 7that a higher intake of carotenoids is associated with a
reduced risk of AMD.332,344,365 In addition, a beneficial effect
was shown for supplementation with lutein and zeaxanthin
on progression to advanced AMD.3e5
3.4.3. Enzymes
3.4.3.1. Superoxide dismutase. Superoxide dismutase (SOD) is
an important antioxidant that catalyzes the conversion of su-
peroxide (O2
) into oxygen and hydrogen peroxide (H2O2).
333
Two families of SOD exist based on their metal ion cofactor:
SOD1 (CuZnSOD), which is localized to the cytoplasmand SOD2
(MnSOD), found in mitochondria.333 The absence of SOD1 or
SOD2 has been associated with early retinal cell degeneration
in mice,129,164 suggesting an important role for SOD in the eye.
With regard to AMD, several reports show elevated
systemic SOD activity in AMD patients compared with
controls,10,155,310,311 others found lowered SOD activity
levels,86,272,346,375,379 and still others measured no significant
association.55,58,68,71,269 One study showed a significant
difference in SOD activity between late and early AMD, with a
lower SOD activity in late AMD patients.86
The association of both low and high SOD serum activity
levels with AMD might be explained by the damaging effects
of both high and low levels of SOD. High levels of SOD lead to
higher H2O2 production, whereas low SOD activity leads to the
continuing presence of O2
molecules. The detrimental effects
of both low SOD and high SOD activity on ROS production
suggest that imbalance of the enzyme activity leads to path-
ological conditions and that proper SOD balance is important
to maintain homeostasis.
3.4.3.2. Paraoxonase 1. Paraoxonase 1 (PON1) is bound to HDL.
PON1 hydrolyzes organophosphates and lipid peroxides and
inhibits the oxidation of LDL.18,153 In addition, PON1 is able to
detoxify homocysteine thiolactone, one of the highly reactive
metabolites of homocysteine.151 Active PON1 interacts with
oxidized proteins or lipids, leading to its own inactivation.17
The low serum PON1 activity levels observed in AMD pa-
tients18,22,341 could be due to inactivation of PON1 after
reacting with oxidized proteins.
3.4.3.3. Catalase. Catalases are important in ROS clearance by
converting hydrogen peroxide (H2O2) to oxygen andwater.
47 In
AMD, 3 studies reported downregulated systemic catalase
activity levels,272,346,374 whereas 3 others reported no differ-
ence in catalase activity levels between AMD patients and
controls.68,86,269
Taken together, dysregulation of the oxidative stress
pathway and the manner in which oxidative stress is
managed by the body seems to play an important role in AMD.
A large number of investigators have reported decreased
levels of antioxidants and elevated oxidized protein or lipid
levels (Fig. 1). The most promising biomarker candidates in
the oxidative stress pathway are MDA and homocysteine,
which were consistently reported to be increased in AMD
patients. For other factors, however, the reported associations
were less clear and with mixed results. This could indicate
that an imbalance of the entire oxidative stress system may
play a role, rather than levels of individual factors of this
system specifically.4. Immunity
The involvement of the immune system in the pathology of
AMD is widely accepted, and some suggest reframing AMD as
an autoimmune disease.39 The activity of the immune system
in AMD, both innate and adaptive, has been implicated at
several levels. Immune cell infiltrates have been shown in the
retinas of AMD patients examined postmortem,198 with
evidence of cytokine/chemokine expression at the affected
site, as described in more detail in Section 4.2.
Strong evidence for the involvement of the immune sys-
tem in AMD also comes from several GWAS studies (described
in Section 1).99,101 In particular, the role of the complement
system is apparent. In the following sections, we discuss
immunity-related compounds, including systemic markers of
the complement system (Section 4.1) and elements of adap-
tive and innate immunity (Sections 4.2e4.4). A complete
overview of the studies and references is provided in Sup-
plementary Table 3.4.1. The complement system
The complement system is an integral part of innate
immunity with essential roles in protection against foreign
intruders via tissue inflammation, cell opsonization, and
cytolysis. It is also involved in monitoring and maintaining
host tissues by clearing cellular debris, maintaining cellular
integrity, tissue homeostasis, and modifying the adaptive
immune responses.105
Ever since histopathological studies demonstrated the
presence of complement components in drusen,11,127 the
involvement of the complement system in AMD has been
studied extensively and genetic evidence showing strong links
between components of the alternative pathway of the
complement system and AMD followed.101,193 Although the
complement system acts locally, its components can also be
detected systemically in serum or plasma. A number of studies
have investigated the expression levels of complement
regulators, complement components, and activation products
in AMDpatients versus controls. An overview of the alternative
pathway of the complement system is provided in Fig. 2.
The central molecule of the complement system is
complement component 3 (C3). Enzymatic cleavage of C3
results in the generation of its active fragments C3a (a potent
proinflammatorymolecule) and C3b that, via several digestion
steps, leads to C3d.220 A number of studiesmeasured systemic
C3 levels but did not find an associationwith AMD,278,298,312,319
whereas higher systemic levels of its active fragments, C3a
and C3d, were detected in AMD patients.130,278,298,319 These
findings suggest that the processing of C3, that is its activa-
tion, may be associated with AMD and a number of studies
have investigated this. Complement activation was measured
as the ratio of C3 and its degradation product C3d (C3d/
C3)280,281,319 or as a cleaved form of C3a (C3a-desArg) in
blood317 and urine.121 Of the 5 studies that investigated
complement activation in AMD, 4 found higher complement
activation levels in AMD patients.280,281,317,319 An association
of C3a-desArg in urine with AMD was not established.121 A
recent study suggests that complement activation levels may
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Fig. 2 e Overview of the alternative pathway of the complement system. Spheres are colored to indicate levels in AMD
patients compared with controls based on literature: upregulated (green), upregulated/no difference (dark green),
upregulated/downregulated (gray), and no difference (yellow). (1) Complement component 3 (C3) splits into C3a and C3b by
spontaneous hydrolyzation or by the C3-convertase (C4bC2) resulting from activation of the classical or lection pathway. (2)
Factor B (FB) can bind C3b to form C3bB. (3) The bound factor B is then cleaved by factor D (FD) which results in the formation
of the C3-convertase: C3bBb (4). This C3-convertase can cleave C3 which leads to more C3b and in turn increased formation
of the C3-convertase (known as the C3 amplification loop). The C3-convertase can also bind another C3b molecule to form
C3bBb3b, which is a C5-convertase (5). This C5-convertase can convert C5 into C5a and C5b. (6) C5b then sequentially binds
C6, C7, C8, and multiple C9 molecules to form the terminal complement complex (SC5b-9), also known as membrane attack
complex. * The C3-convertase is inhibited by several complement regulators, among which decay accelerating factor (DAF)
and factor H (FH). ** Factor I (FI) can breakdown C3b via several digestion steps to C3c and finally C3d, this protease activity,
however, requires a cofactor, such as FH.
s u r v e y o f o p h t h a lmo l o g y x x x ( 2 0 1 7 ) 1e3 18decrease at more advanced stages of the disease, but this
finding needs to be confirmed in prospective AMD cohorts.320
Besides C3, complement component 5 (C5) is also essential
in the activation cascade because it serves as the entry point
for the formation of the terminal complement complex
(SC5b-9).220 The activation product of C5, C5a, is a potent
anaphylatoxin. Increased levels of C5a were detected in most,
but not all130 studies examining the role of C5a in
AMD.278,298,319 These same studies also tested whether SC5b-9
is associated with AMD. Higher SC5b-9 levels were detected inAMD in 1 study,298 but the other 2 studies found no evidence
for an association.278,319
The activity of the complement system is tightly controlled
by regulatory factors that ensure appropriate, but not excessive,
generation of terminal complexes. Among others, they include
complement FH (encoded by the CFH gene), factor I (FI, encoded
by CFI ), FB (encoded by CFB), factor D (FD, encoded by CFD), and
decay accelerating factor (DAF/CD55, encoded by CD55).220
Genetic association studies showed strong evidence of an
association between the CFH gene and AMD.101 Systemic
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ever. Four studies report lower FH levels in AMD,14,278,308,310 1
study detected higher levels of FH in AMD,128 and another 4
studies did not find an association with AMD.120,298,312,319
Similar to FH, FI also inhibits the activity of the com-
plement system through inactivation of C3b. Genetic evi-
dence for FI involvement in AMD has been shown
previously, but no conclusive evidence links FI levels to
AMD in general. One study reports increased FI levels in
AMD,312 another reports decreased levels but only in pa-
tients carrying a rare genetic variant in CFI,343 and 2 did not
find any association.278,319
The findings for FB and FD levels in AMD are also inconsis-
tent. Three studies reported higher FB levels in AMD pa-
tients,130,298,319 whereas 2 others did not detect an association
with AMD.278,312 Similar results were described for FD, where 3
studies reported higher FD levels,130,298,326 1 study reported
lower levels in AMD,312 and another found no association with
AMD.278 Finally, 2 studies that examined the role of CD55 did
not find evidence for an association with AMD.123,314
In summary, not only genetic studies but also studies
measuring complement components provide evidence that
link complement activation to AMD (Table 2). Some factors,
however, should be taken into account when considering the
use of systemic complement activation levels as a biomarker
for AMD in individual patients. Often antibody-based tests do
not discriminate between the total amount of a specific
complement factor and its processed activated part, as
cleavage of the proform to the active mature form cannot be
distinguished by the reagent. Moreover, complement activa-
tion levels are subject to high variability, and other causes of
increased complement activity should be excluded because
increased complement activationmay reflect immune system
activity that is not necessarily connected to disease progres-
sion. Linking exacerbated complement activation in an indi-
vidual patient to his or her genetic blueprint is potentially
more useful. For example, haplotypes and combinations of
genotypes in several complement genes have been associated
with increased complement activation levels.1308,266 In
addition, several investigations have now demonstrated that
FI levels are lower in AMD patients carrying rare genetic var-
iants in the CFI gene.107,172,343 For FH levels, there were similar
associations with genotype. Some but not all rare variants in
the CFH gene were associated with reduced FH levels.337,349,378
Thus, patients carrying rare variants in complement genes
tend to have higher complement activation levels than
AMD patients in general.106 These insights may benefit
ongoing clinical trials on the effectiveness of complement
inhibitors and could prioritize patientswho carry rare variants
in these genes.
4.2. Cytokines
4.2.1. Interleukins
Cytokines are a large family of small proteins that play a
pivotal role in cell signaling. An important group of cytokines
are interleukins. Interleukins play a key signaling role in the
inflammatory response. Interleukin-6 (IL-6) is a cytokine with
many described functions,215,225 and its relationship to AMD
has been investigated. A number of studies reported increasedlevels of IL-6 in AMD patients,7,124,191 but the majority found
no association with AMD in general.15,58,183,188,231,240,290,352,367
Notably, a number of these studies did find an association in
subgroup analyses. For instance, an association with AMD
was reported only in patients with high IL-6 levels58 or the
association with IL-6 was established only for GA patients.188
In addition, only the highest tertile of IL-6 levels was associ-
atedwith progression of AMD in a prospective cohort study.303
Other interleukins have also been studied in relation to
AMD, although to a lesser extent. In most studies, these in-
terleukins were measured in a multiplex analysis of inflam-
matory markers. Two studies measured multiple interleukins
in serum.231,240 In 1 study, there were higher serum levels of IL-
1b, IL-4, IL-5, IL-10, and IL-13 in patients with nAMD,240 but
these factors were not associated with early, atrophic, or neo-
vascular AMD in another study.231 Higher serum levels of IL-1a
and IL-17 in nAMD patients were only reported in the first
study. In addition, no association was found for IL-2, IL-12, and
IL-15.240 Other studies also detected no association between IL-
2,188 IL-15,89 and AMD. For IL-8, although no association was
present in 2 studies,229,235 a third larger study described higher
IL-8 levels in AMD patients, in particular in dry AMD.7 Higher
IL-18 levels were reported in dry, but not nAMD, in 1 study.143
A second study did not find different levels between different
types of AMD and controls.89
Although most studies focused on systemic levels of
interleukins, a small number performed measurements in
aqueous humor290 and vitreous.383 Higher IL-1b levels were
found in the vitreous of nAMD patients.383 In aqueous humor,
IL-1a and IL-15 were upregulated and IL-13 was down-
regulated, whereas for IL-2, IL-4, IL-8, IL-10, IL-12, and IL-17, no
differences were detected.290
4.2.2. Chemokines and chemokine receptors
Chemokines (chemotactic cytokines) have the ability to direct
movement of cells through receptor-mediated chemotaxis.
Evidence from postmortemmaterial and animal models have
implicated infiltrating immune cells in pathological eye tis-
sues, suggestive of the involvement of chemokines in these
environments.200,287,305,329
Chemokine ligand 2 (CCL2; or monocyte chemoattractant
protein 1) attracts C-C chemokine receptor type 2 (CCR2)-
expressing monocytes into tissues and is one of the most
studied chemokines in AMD. Five relatively small, case-control
studies did not find an association between levels of CCL2 and
AMD,90,116,120,231,290 but several larger studies did see an asso-
ciation with increased levels of CCL2.9,310,382 This effect was
also reported in a cross-sectional study linking higher levels of
urinary CCL2 to early AMD.121 Overall, these findings support
the notion that CCL2 is involved in AMD. Interestingly, CCR2-
expressing cells can also be detected systemically, and both
decreased and increased levels have been associated with
AMD.9,115 Two other studies did not find any association.94,376
Another receptor involved in the recruitment of monocytes,
CX3C receptor 1, was measured in two AMD studies.92,116 Only
the more recent study reported CX3C receptor 1 to be upregu-
lated in both early and neovascular AMD.92
Eotaxin (eosinophil chemotactic protein/CCL11) and
closely related eotaxin-2 (CCL24) attract eosinophils. These
are interesting molecules for AMD pathogenesis because
Table 2 e Overview of studies measuring complement components in AMD patients compared with controls
Component Upregulation No difference Downregulation
C3 Scholl et al, 2008298
Reynolds et al, 2009278
Silva et al, 2012312
Smailhodzic et al, 2012319
C3a Scholl et al, 2008298
Reynolds et al, 2009278
C3d Scholl et al, 2008298
Hecker et al, 2010128
Smailhodzic et al, 2012319
C3a des Arg Sivaprasad et al, 2007317 Guymer et al, 2011121
C3d/C3 Smailhodzic et al, 2012319
Ristau et al, 2014280
Ristau et al, 2014281
C5a Scholl et al, 2008298
Reynolds et al, 2009278
Smailhodzic et al, 2012319
Hecker et al, 2010130
SC5b-9 Scholl et al, 2008298 Reynolds et al, 2009278
Smailhodzic et al, 2012319
FH Hakobyan et al, 2008128 Scholl et al, 2008298
Silva et al, 2012312
Smailhodzic et al, 2012319
Guymer et al, 2015120
Reynolds et al, 2009278
Ansari et al, 201314
Sharma et al, 2013308
Sharma et al, 2013310
FI Silva et al, 2012312 Reynolds et al, 2009278
Smailhodzic et al, 2012319
Van de Ven et al, 2013a,343
FB Scholl et al, 2008298
Hecker et al, 2010130
Smailhodzic et al, 2012319
Reynolds et al, 2009278
Silva et al, 2012312
FD Scholl et al, 2008298
Hecker et al, 2010130
Stanton et al, 2011326
Reynolds et al, 2009278 Silva and colleagues 2012312
DAF/CD55 Haas et al, 2011123
Singh et al, 2012314
a Significant downregulation of FI was described in a subgroup of patients with a rare variant in the CFI gene.
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choroidal neovascularization.91,309 CCR3 is expressed on
choroidal neovascular endothelial cells and signaling through
this receptor leads to endothelial proliferation, even without
the involvement of eosinophils or other immune cells.
Blocking CCR3 signaling in animals led to a potent inhibition
of neovascularization, even stronger than blocking VEGFA
signaling.329 Levels of CCL11 were investigated in 2 studies,
one reporting increased levels in AMD,231 and the other
finding no differences.91 Supportive of the aforementioned
findings, 2 studies of the same group reported CCL24 to be
upregulated in AMD.309,310 Despite these overall promising
results, systemic elevations of CCR3 on immune cells have not
yet been reported. The only study investigating CCR3 on
granulocytes reported no association, although there was a
trend toward higher expression of CCR3 in nAMD.91 Taken
together, the CCL11/CCL24-CCR3 axis is potentially involved
in humanAMDpathology, but it is not yet clear whether this is
mostly a local signaling, mediated through CCR3 expression
on endothelial cells, or whether systemic CCR3-expressing
cells could also be involved.
The chemokine ligand CXCL10, also known as interferon
gamma-induced protein 10, attracts a range of cell types and is
an inhibitor of angiogenesis.13 Two studies showed noassociation with CXCL10 in serum or plasma and AMD,93,116
and only 1 study showed elevated serum CXCL10 levels in
AMD patients.231 Of interest is a recent publication, showing
upregulation of CXCL10 in aqueous humor of AMD patients
compared with controls undergoing cataract surgery,290 sug-
gesting that the effect of this chemokine might be local.
The receptor for CXCL10 is CXCR3 which is expressed on a
variety of cell types. Only one study investigated numbers of
CXCR3-expressing cells peripherally and detected reduced
presence of CD8þ T-cells expressing CXCR3 in AMD,93 but
additional research is warranted before concluding whether
the CXCL10-CXCR3 axis can be reliably used as a biomarker
for AMD.
It has been suggested that stem cell progenitor cells are
involved in the disease etiology of AMD. Chemokine ligand
CXCL12, also known as stromal cell-derived factor 1, plays a
role in the movement of these stem cell progenitor cells
throughout the body. Four small case-control studies have
investigated the plasma levels of stromal cell-derived factor 1
in AMD patients with mixed results. Two studies, by the same
group, report significantly lower levels of stromal cell-derived
factor 1 in patients with nAMD,210,211 whereas another study
showed the inverse effect,299 and the fourth did not report any
differences between nAMD and control individuals.115
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4.2.3.1. Tumor necrosis factor alpha. Tumor necrosis factor
alpha, an important marker for systemic inflammation, has
been investigated as such in several studies; however, no
significant associations betweenAMDcases and controlswere
reported in serum or plasma.120,124,183,188,231,240,380 Increased
levels of soluble tumor necrosis factor alpha receptor 2 were
reported in a case-control study in early and neovascular
AMD,89 which in a large population-based study did not reach
statistical significance, but there was a trend toward upregu-
lation in early AMD patients.191
4.2.3.2. Interferon gamma. Interferon gamma is an important
cytokine in both innate and adaptive immunity as it induces
cellular response to infections.297 Three studies measured
interferon gamma in AMD cases and controls, but none found
an association with AMD.89,231,2404.3. Other immune factors
4.3.1. C-reactive protein
C-reactive protein (CRP) is a marker of inflammation and a so-
called acute phase protein because its levels change quickly
upon disturbances of homeostasis. Evidence regarding the
possible relation of this proteinwith AMD is inconclusive, with a
roughly equal number of studies reporting higher CRP levels in
AMDpatients7,56,57,138,174,228,282,290,301,302,304,342,347,356,376 ornoclear
evidence for an association.33,58,65,120,134,141,161,185,217,285,312,315,327
Those that used a more precise measurement of CRP (high-
sensitivityCRP)were alsonot able to provide conclusive results: 5
studies detected higher levels of high-sensitivity CRP in AMD
patients,32,124,191,230,295 compared with 5 that did not show an
association with AMD.15,183,188,352,367
4.3.2. (Soluble) Intercellular adhesion molecule and vascular
cell adhesion molecule
Intercellular adhesion molecule and vascular cell adhesion
molecule are immunoglobulins that are usually upregulated
on cell surfaces after immune signaling has taken place.48
They form a sticky surface to which immune cells that ex-
press integrins can adhere. These molecules and their soluble
counterparts are rarely investigated alone but usually as part
of a panel that measures inflammatory activity. For intercel-
lular adhesion molecule, 1 study reported higher levels to be
associated with the incidence of AMD in women,295 whereas 6
others did not find any association.120,134,183,191,352,367 In the
case of vascular cell adhesion molecule, 1 study measured
higher levels in AMD patients,191 whereas 2 studies did not
find any association with AMD.120,134 In addition, no associa-
tion with AMD progression and either Intercellular adhesion
molecule or vascular cell adhesion molecule was reported.303
4.3.3. White blood cell count
As mentioned previously in Section 4, a clear link with
inflammation and inflammatory processes and AMD has been
established, and several immune competent cells have been
implicated in the disease etiology. As a result of local
stress or inflammation, the body may respond by cellular
proliferation of immune cells and recruitment of these cells tothe affected site. From this perspective, white blood cell count
is an interesting parameter to measure in AMD. A
relatively large number of studies have investigated
white blood cell count in AMD, and some did detect increased
white blood cell numbers.31,181,182,191,307,356 This
contrasts with most studies that did not find any
association.50,113,149,157,180,181,183,185,187,205,285,315,352,367 Never-
theless, white blood cell count may still be considered as a
potential biomarker for AMD if the analysis is performed in
the context of a different theoretical framework. It is
conceivable that it is not the total number of cells that change
but rather the ratio between different cell types. Supporting
this notion, a higher neutrophil/lymphocyte ratio has been
associated to AMD and AMD subtypes.148 A more in-depth
analysis of the different cellular subtypes, such as the rela-
tive expression of cytokine/chemokine receptors, would offer
more insights.
4.3.4. Pentraxin-3
Pentraxin-3 (PTX3), like CRP, belongs to the pentraxin super-
family. Upon inflammation, PTX3 is produced locally by the
RPE162 and can interact with complement component C1q and
enhances activation of the classical and lectin pathways of the
complement system. In addition, PTX3 attracts complement
FH, thereby inhibiting the amplification loop and preventing
excessive activation of the alternative pathway.76,162 Although
1 case-control study reported higher plasma PTX3 levels in
nAMD,228 a more recent study (including also early AMD and
GA patients) could not replicate these findings.162 The latter
study did however describe an increased expression of the
PTX3 gene with age- and inflammation-induced apical PTX3
secretion of the RPE.162 Taken together, this suggests a more
local expression of PTX3 in AMD; however, measurements of
PTX3 locally in vitreous samples have not yet been performed
and would therefore be a target of further research.
4.4. Antibodies
4.4.1. Antiretinal autoantibodies
The formation of antibodies against foreign epitopes is a key
element of immunity.When endogenous epitopes become the
trigger for mounting an immune response, autoimmunity
ensues.271 Antibodies against epitopes found in retinal mate-
rial of AMD patients have been investigated in various studies.
Several studies demonstrated upregulation of circulating
antiretinal autoantibodies (ARAs) in the serum of AMD pa-
tients.49,119,264,268 Although one study showed similar levels of
ARAs in cases and controls, it did show a difference in types of
antibodies specific for each disease stage.2 In addition, higher
concentrations of circulating ARAs were detected in
treatment-naive nAMD patients compared with con-
trols.196,197 These levels also correlated to lesion size.197 After
the loading phase of anti-VEGF treatment, autoantibody levels
decreased.196,197 Moreover, correlations were reported be-
tween ARA levels and improvement of visual acuity, fluid
reduction on optical coherence tomography, and decreased
leakage on fluorescein angiography after 3 months.197
Furthermore, other studies attempted to identify specific
circulating ARAs associated with AMD.145,156,232 Surprisingly,
one study showed not only upregulation of antibodies but also
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concentrations were reported for a-crystallin, whereas a-
enolase and glial fibrillary acidic protein antibodies were both
significantly higher in serum of AMD patients.156 The latter
finding is supported by results from a previous study which
showed different staining patterns in serum of AMD patients,
with the most frequent pattern observed being almost iden-
tical to that using antiglial fibrillary acidic protein anti-
bodies.268 In addition, using an untargeted approach, 1 study
identified 4 novel retinal antigens in serum of AMD patients:
retinol binding protein 3 (Rbp3), aldolase C, pyruvate kinase
isoform M2, and retinaldehyde binding protein 1.232 Because
Rbp3 and retinaldehyde binding protein 1 were previously
reported in other ocular diseases, this study focused on
aldolase C and pyruvate kinase isoform M2. A significant
higher reactivity to aldolase C in nAMD, but not in early AMD,
was reported. Because reactivity to pyruvate kinase isoform
M2 was higher in both AMD groups compared with controls,
this could potentially be a biomarker for the development of
AMD.232 A more recent study with a similar approach also
identified ARAs with higher reactivity in AMD; heat shock
70 kDa protein 8 and 9, a-crystallin A chain, annexin A5, and
protein S100-A9.145
4.4.2. Other autoantibodies
Serum autoantibodies have been extensively investigated by
Morohoshi and colleagues using an antigen microarray anal-
ysis containing 85 autoantigens. Serum of AMD patients and
controls showed a different IgG and IgM autoantibody profile,
andmultiple autoantibodies were significantly higher in AMD.
In addition, they calculated IgG/IgM ratios for the antibodies
and evaluated whether this ratio correlated to disease
severity. Antiphosphatidylserine IgG/IgM was significantly
elevated in AMD and correlated best with AMD stage. More-
over, reactivity to phosphatidylserine was highly increased in
retina of AMD patients compared with controls.232
Other investigators focused specifically on anti-
phospholipid antibodies, which are reported to be found in
aging people and diseases associated with aging.257 In this
study, anticardiolipin IgG levels were associated with AMD,
supported by the findings of Morohoshi and colleagues which
showed higher expression of anticardiolipin antibodies in
nAMD compared with controls.233,257
As described in Section 3.1, anti-CEP antibodies have also
been investigated in association with AMD.117,118,242
4.4.3. Antibodies against pathogens
Infection by pathogens leads to increased antibody titers of
the foreign pathogen. Several infectious agents have been
implicated in AMD, and we detail the antibodies against these
pathogens in this section.
Chlamydia pneumoniae is an intracellular bacterial species
that has been linked to atherosclerosis.137 Since AMD involves
inflammatory processes similar to atherosclerosis, the asso-
ciation of Chlamydia pneumoniae with AMD was explored. One
small case-control study found support for thiswith increased
antibody levels in AMD patients,167 whereas 4 larger studies
did not find evidence for a relation between anti-Chlamydia
pneumoniae antibodies and AMD.183,188,227,283The cytomegalovirus is another infectious agent that has
been hypothesized to be associated with the pathogenesis of
AMD, based on the relation between inflammatory processes
induced by infection and the resulting vasculopathy.227 Only 2
studies investigated this association. One found no evidence
for an association,90 whereas the other described higher levels
of antibodies against cytomegalovirus in nAMD compared
with controls and dry AMD.227
Another infectious agent possibly involved in the patho-
genesis of AMD is Helicobacter pylori. Two studies have tested
an association between antibodies against Helicobacter pylori
and AMD but found no evidence for this, even when dis-
tinguishing between dry and neovascular AMD.188,227
To summarize the most important findings regarding
immune-related factors, involvement of the complement
system in AMD is evident and complement activation prod-
ucts seem to be good biomarker candidates. Increased levels
of inflammatory factors, such as CCL2 or CRP, have been
frequently reported and support the notion that inflammatory
processes underlie AMD. Yet, these are not specifically related
to AMD and may therefore not be the best biomarker for
clinical implementation. The use of multiplex assays for the
simultaneous detection of multiple inflammatory markers
(cytokines and chemokines) holds great promise, but addi-
tional data are required to determine their usefulness as AMD
biomarkers. In addition, ARAs are also associated with AMD,
but at present, it is unclear whether these autoantibodies play
a direct role in the etiology of the disease or rather are the
result of retinal damage. Further research is therefore
necessary to determine if (specific) ARAs could be used as a
biomarker for AMD.5. Lipid metabolism/homeostasis
Lipidmetabolism is one of themajor pathways involved in the
pathogenesis of AMD as evidenced by genetic associations of
lipid-linked genes CETP, LIPC, ABCA1, and APOE.99,101 More-
over, drusen, the major hallmark of AMD, consists of at least
40% lipids.126,350 In addition, asmentioned in Section 4.4, there
are similarities in the pathogenesis of atherosclerosis and
AMD.368 Because lipids are important risk factors for athero-
sclerosis and CVD,207 these might also be associated with
AMD. Numerous studies have measured lipid levels in serum
or plasma, and the results of these studies are summarized in
Sections 5.1 to 5.4. We focus on studies that reported associ-
ations with AMD and results from large population-based
studies. A complete overview of all studies and references is
provided in Supplementary Table 4.
5.1. Lipids
Cholesterol has multiple functions. It is required for building
and maintaining cell membranes, is involved in cell signaling
processes, and is a precursor molecule for synthesis of steroid
hormones, bile acids, and vitamin D.131
The population-based Cardiovascular Health Study re-
ported lower levels of total cholesterol in AMD patients, of
which the majority had early AMD.185,217 Also in the Beaver
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development of early AMD inwomen,182 and therewas a trend
for lower levels of cholesterol in nAMD186; a more recent
analysis of the Beaver Dam Eye Study data, however, did not
show an association betweenAMD and cholesterol levels.183 In
addition, 2 case-control studies described lower levels of
cholesterol in AMD patients.36,267 In contrast, higher choles-
terol was associated with AMD in 10 studies, although these
were all case-control studies, and only half studied
nAMD.8,57,67,88,97,109,134,152,246,342 The vast majority of studies
(Supplementary Table 4), however, did not demonstrate a
difference in cholesterol levels between AMD patients
and controls, including a meta-analysis of 3 large population-
based studies,190 and several large population-based
studies.33,37,42,50,61,73,141,143,157,160,161,176,177,184,199,261,304,306,321,331,
345,354,367,371
Triglycerides are molecules that have a glycerol backbone
connected to 3 fatty acids of variable length. Most studies did
not report differences in triglyceride levels between AMD
cases and controls (Supplementary Table 4). Lower triglycer-
ide levels were reported in early AMD,185,371 nAMD,219 and any
AMD.33,177,265,285,304 In contrast, 3 studies reported a higher
level of triglycerides to be associated with AMD,67,235,246 of
these, 1 study included only women,245 and 1 study found the
association in women only.235
Phospholipids are another class of lipids and are an impor-
tant component of cell membranes. In 3 studies, no association
was found between phospholipids and AMD.1,40,292
5.2. Lipoproteins
Because of the insoluble nature of lipid molecules, lipopro-
teins are needed for transportation of lipids through the
circulation. Five different lipoproteins exist, differing in their
density and size: chylomicrons, very lowedensity lipoprotein,
intermediate-density lipoprotein, LDL, and HDL.255 Both HDL
and LDL carry cholesterol between the liver and periph-
ery.131,208,265 The association between these 2 lipoproteins and
AMD has been extensively studied.
For AMD, higher levels of LDL-C were found in several
studies. Half of these studies found this association when
comparing controls to nAMD,109,152,154,279,342 others found an
association in early AMD,273 any AMD,57,67 and in womenwith
dry AMD.246 Almost all other studies, including multiple large
population-based studies,33,37,50,61,184,304,331,354,371,377 did not
report an association between AMD and LDL-C
(Supplementary Table 4). Only the Cardiovascular Health
Study associated lower LDL-C levels with early AMD pa-
tients185 and reported a trend toward lower levels in patients
with any AMD.217 Differences in results regarding LDL-C levels
can be partly due to different measurement methods across
studies, as it can either bemeasured directly, butmore often is
estimated using the Friedewald equation.98
Since HDL cholesterol (HDL-C) is inversely associated with
CVD, one may have expected to also find this inverse associ-
ation with AMD. Surprisingly, lower HDL-C levels were only
described in a few studies in varying AMD stages; in late
AMD,279,331 in women with dry AMD,246 and in early AMD.180
Increased HDL-C levels in AMD patients were present in
multiple studies.15,35,50,61,73,141,144,161,182,184,186,265,304,345,356,376 Itmust be noted that most of these studies only found a weak
association in a subgroup of AMD patients. Most of the studies
did not describe significant differences in HDL-C levels
(Supplementary Table 4).
Three studies evaluated non-HDL-C, which is calculated by
subtracting HDL-C from total cholesterol. Two studies,
including a large meta-analysis of 3 population-based studies,
reported no association with AMD,190,265 whereas the third
study found higher non-HDL-C to be associated with any
AMD.57
Lipoprotein (a), Lp(a), is an LDL-like particle, which consists
of apolipoprotein-B100 and apoliprotein-A. Its precise func-
tion is unclear, but higher levels of Lp(a) have been repeatedly
associated with CVD.82,171 Contrarily, no association of Lp(a)
levels with AMD or progression of AMD has been described so
far.1,57,83,94,185,246,3035.3. Apolipoproteins
Apolipoproteins bind lipids to form lipoproteins that are
responsible for lipid transport. They also function as enzyme
cofactors and receptor ligands.1 There are several classes of
apolipoproteins. The overview presented in this section is
restricted to apolipoprotein A1 (ApoA1), the major component
of HDL-C, apolipoprotein B (ApoB), mostly found in LDL-C, and
apolipoprotein E (ApoE), found in IDL-C and chylomicrons.
Several investigations found an association between apoli-
poproteins and AMD or features of AMD.1,73,94,246,265 The Pa-
thologies Oculaires Lie´es a` l’Age (POLA) study described
ApoA1 to be associated with an increased risk of soft drusen73
and also in the European Genetic Database (EUGENDA) cohort,
higher levels of ApoA1 were associated with AMD, even after
adjustment for genetic variants that influence lipid levels.265
In contrast, one study reported a lower ApoA1 concentration
in womenwith dry AMD.246 This study also described a higher
concentration of ApoB in dry AMD cases, which is in concor-
dance with another study.94 Higher ApoE levels were reported
in advanced AMD compared with early AMD and control in-
dividuals; this difference could be due to a higher allelic
burden of the APOE gene in these patients.1 Other studies did
not describe an association between ApoA1, ApoB, or ApoE
and AMD.57,66,83,1855.4. Fatty acids
There are different types of fatty acids. PUFAs usually derive
from phospholipids or triglycerides.245,254 The most
commonly studied PUFAs in AMD are the omega-3 fatty acids
DHA and eicosapentaenoic acid (EPA). Fish and other seafood
are the main source of these omega-3 PUFAs.219,221 Animal
and epidemiological studies have shown a lower risk for AMD
in subjects with high dietary intake of omega-3 fatty
acids.21,324 Also 2 interventional studies with omega-3 fatty
acid supplementation have been performed; the Age-related
Eye Disease Study 2 showed no beneficial effect for omega-3
fatty acid supplementation,3 whereas the Nutritional AMD
Treatment 2 study showed a protective effect for DHA sup-
plementation only in patient homozygous for the major allele
(T) of the Y402H variant in the CFH gene.222
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number of studies investigated plasma or serum levels of
these factors. In the Antioxydants, Lipides Essentiels, Nutri-
tion et maladies Oculaires (ALIENOR), a population-based
study, advanced AMD cases had lower plasma levels of a-
linoleic acid and DHA compared with no or early AMD. In
addition, lower plasma levels of EPA were associated with
GA.221 This is in line with baseline measurements performed
in the Nutritional AMD Treatment 2 study that showed that
nAMD cases had lower EPA and DHA levels in red blood cell
membranes and lower serum EPA.219 On the contrary, smaller
case-controls studies reported no effect or opposite effects for
DHA, EPA, and a-linoleic acid.165,252,254,292 For plasma or serum
levels of docosapentaenoic acid, another omega-3 fatty acid,
no significant associations were described.165,221,292
Omega-6 fatty acids, arachidonic acid and linoleic acid, and
omega-9 fatty acid, oleic acid, have also beenmeasured. A small
case-control study found lower levels of linoleic acid and oleic
acid, and higher levels of arachidonic acid in the membranes of
erythrocytes of AMD patients.254 In line with these findings, a
recent study reportedhigher serumarachidonic acid innAMD.252
Two larger case-control studies, however, did not show different
levels of these omega-6 and omega-9 fatty acids.165,292
Regarding saturated fatty acids (which are single bonded),
lower levels of palmitic acid in erythrocytes of AMD patients
were reported in a small, case-control study,254 although
systemic levels were not different between cases and con-
trols.165,254 Also for stearic acid, no association with AMD was
detected.165,254
Evidence for the involvement of lipids in AMD comes from
epidemiologic, molecular, and genetic studies, but the exact
role of systemic lipid levels is not yet clear. These studies are
complicated by high variability of lipid and fatty acid levels in
general and are potentially further confounded by the use of
medication and/or dietary intake, including supplements.
Although a combination of factors could constitute a risk
profile thatmay be linked to the development and progression
of AMD, it is unlikely that these factors individually could act
as proper biomarkers for the disease.6. Extracellular matrix
Remodeling of the ECM plays a role in the pathogenesis of
AMD.158,241 Drusen development, as well as alterations of
Bruch membrane52,59 and infiltration of immune cells, relate
to a balance between structural tightness or looseness of the
extracellular environment. The constant remodeling of the
ECM is carefully regulated by matrix metalloproteinases
(MMPs) and tissue inhibitors of metalloproteinases.236 Dysre-
gulation of MMPs and/or tissue inhibitors of metal-
loproteinases could lead to ECM changes seen in AMD, and
therefore, these are potentially useful biomarkers for AMD.
Genetic variations in several ECM-related genes are asso-
ciated with AMD99,101,275; however, only few studies have
measured plasma or serum levels of MMPs and tissue in-
hibitors of metalloproteinases.45,46,120,188,381 An overview of
the studies and references is provided in Supplementary Table
5. Upregulation of MMP9 in plasma was associated with AMD
in 1 study45; however, 2 other studies could not replicate thesefindings.120,381 No association was found for serum MMP1
levels120,381 or MMP2 in serum or plasma.45,120,381
All 3 studies were limited because of small samples sizes
and the measurement techniques used. Moreover, in these
studies, both the proenzyme and active forms were measured
together. Increased immunoactivity of MMPs does not
necessarily mean an increase in enzymatic activity. Other
measurement techniques are required to measure MMP ac-
tivity more reliably, and larger future studies are needed to
elucidate the potency of MMPs as biomarkers for AMD.
One of the main constituents of the ECM in Bruch mem-
brane is elastin.241 Elastin, in combination with other proteins
of the ECM,348 provides strong and long-lasting elasticity to
the Bruch’s membrane. The elastin layer degrades with age,
however, and elastin metabolism may contribute to AMD
where there is frequently thinning and fragmentation of the
elastic layer,52 especially in relationship to choroidal neo-
vascularization.31,133 There is also evidence for abnormal
systemic elastinmetabolism in AMD. Patients with nAMDhad
significantly increased susceptibility to elastolysis in the
skin.31 Patients with nAMD had significantly higher levels of
serum elastin-derived peptide levels,318 probably due to the
aforementioned elevated levels of MMPs in serum.45 Apart
from elevated elastin peptide fragment levels, sera from pa-
tients with AMD contain specific autoantibodies against
elastin and it has been suggested that the IgG/IgM ratio for
elastin, and other, autoantibodies might allowmonitoring the
progression of AMD.233 Therefore, analyzing elastin degrada-
tion products or autoantibody levels or ratios might be useful
tools as biomarkers, at least for nAMD.7. Dietary factors
Known risk factors for AMD include dietary factors, such as low
intake of antioxidants. Some vitamins are antioxidants,
whereas others act as cofactors for enzymes involved in ROS
clearance,333 as detailed inSection7.1. Trace elementshavealso
been hypothesized to be involved in the pathogenesis of AMD
and are described in Section 7.2. Another marker influenced by
diet is serum albumin; this is considered to be an indicator of
nutritional status and inflammation and is discussed in Section
7.3. In addition, diet is also an important source for fatty acids
and carotenoids both related to AMD. These are described in
Sections 3.4.2 and 5.4, respectively. A complete overview of the
studies and references is provided in Supplementary Table 6.
7.1. Vitamins
Vitamin C can act as an ROS scavenger, and it mediates
reactivation of vitamin E.333 When vitamin C hydrolyzes and
reactivates vitamin E, the molecule itself is inactivated, and
hydrolysis by GSH can reactivate vitamin C (Fig. 1).258 Lowered
levels of vitamin C result in less vitamin E conversion to its
active form. In addition, vitamin C itself cannot fulfill its
antioxidant function, and as a consequence ROS production
will rise.258 Vitamin C levels were found to be lower in AMD
patients than those in controls311 and lower in advanced
versus early AMD313; however, most studies do not report an
association between vitamin C and AMD.30,72,87,88,360,375
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prevents lipid peroxidation.333 Lower levels of serum vitamin
E in AMD patients were reported.25,214,313,360 However, asso-
ciations with vitamin E were not conclusive because no
difference in vitamin E levels has been found in several
studies.31,40,72,87,88,224,292,311,322,339
One study reported lower levels of vitamin A in patients with
nAMD.384 However, most studies did not find a significant as-
sociation between vitamin A levels and AMD.31,72,88,224,292,313,360
B vitamins are essential molecules in homocysteine meta-
bolism and synthesis of methionine. Both vitamin B9 (folate)
and B12 (cobalamin) act as cofactors to convert homocysteine
into methionine.294 In AMD patients, lower serum levels of
vitamin B12 were detected compared with controls.113,168,284
These results were not consistently replicated, as equal levels
of serum vitamin B12 in patients and controls have also been
described.132,247 Folate levels were similar between controls
and AMD patients in all studies.113,132,168,183,247,284
Vitamin D can be produced in the dermis upon sunlight
exposure or can be obtained through diet. For its activity, the
molecule has to be converted into its active form in the liver
and kidney before it can regulate uptake of nutrients such as
iron, calcium,magnesium, and zinc.244 There are inconsistent
results for vitamin D levels in AMD patients. They have been
described to be higher,177 lower,150,259 or not associated with
the disease.50,62,111,226,234,261,316
7.2. Trace elements
Trace elements are required by the human body in very low
concentrations for proper physiological functioning; however,
deficiency or excess amounts may be harmful.27
Iron is essential for retinal functioning, as photo-
transduction is dependent on iron-containing enzymes.
Accumulation of iron, however, can be harmful. Iron can
convert hydrogen peroxide (H2O2) into highly reactive ROS and
thereby enhance oxidative stress.323 Cadmium can also in-
crease ROS formation361 and mercury can decrease oxidant
defense mechanisms,140 both leading to increased oxidative
stress. In contrast, manganese, copper, and zinc contribute to
antioxidant activity as they are cofactors for the antioxidant
enzyme SOD.333,362 GSHP is dependent on the presence of the
essential heavymetal selenium.17 In addition, copper and zinc
are able to stabilize proteins, reducing their vulnerability to
oxidation362 but can also lead to pathological aggregation or
even precipitation of proteins.237e239 Both zinc and manga-
nese can reduce uptake or accumulation of toxic cadmium.293
Several studies reported elevated cadmium levels in
blood,50,176,262,366 aqueous humor,163 and urine of AMD pa-
tients.366 Measurement of cadmium levels in blood might
represent only recent cadmium exposure, whereas urinary
cadmium reflects long-term exposure to cadmium and might
therefore be a more accurate biomarker. A study comparing
both blood and urinary cadmium levels did not show an asso-
ciation with AMD in the total study group; however, when
stratified for smoking status, increased urinary cadmium levels
were associatedwith AMD in smoking individuals, suggesting a
smoke-related association of cadmiumwith AMD.81 Lead levels
were elevated in serum and urine of both early and advanced
AMD,50,262,366 and 1 study reported an association between leadand AMD only for women.143 Levels of mercury were only
elevated in patients with advanced AMD.50,262
Selenium was in general not associated with AMD.87,88,163
One study found a borderline significant association with
AMD,339 and another measured significantly lower levels of
selenium in nAMD patients.216 Conflicting results are reported
for levels of iron,31,163,369 copper,40,163 manganese,163,262 and
zinc.24,88,163,262,313
7.3. Albumin
Albumin is essential for maintenance of plasma colloid
oncotic pressure, acts as a plasma binding protein, and also
has antioxidant activity.202 In addition, albumin is one of the
most common proteins found in drusen.63 A few studies
measured serum albumin in AMD patients and controls. Two
case-control studies did not show a significant association
between serum albumin and AMD.31,88 The population-based
Cardiovascular Health Study and Beaver Dam Eye Study did
report significantly lower serum albumin levels in early and
neovascular AMD, respectively.185,187 A more recent nested
case-control study within the Beaver Dam population further
analyzing these data could not confirm decreased albumin
levels in AMD.183
Taken together, because of the highly variable diet
between subjects, and varying levels of dietary factors within
subjects based on fasting state, assessment of the role of these
dietary factors as biomarkers in AMD remains difficult.
Dietary intake and/or supplementation of antioxidants and
vitamins, however, have therapeutic benefit. The Age-related
Eye Disease Study trial, one of the largest investigations into
vitamin supplementation in AMD, focused on daily supple-
mentationwith vitamin E, vitamin C, b-carotene, and zinc and
demonstrated a lower chance of advanced AMD development
in subjects taking these supplements.4 In the Age-related Eye
Disease Study 2, an improved formula was evaluated and
b-carotene was replaced by lutein/zeaxanthin because of the
increased risk of lung cancer in smokers.3,5
Regarding trace elements, toxic heavymetals (such as lead,
mercury, and cadmium) are mainly associated with an
increased risk of AMD, whereas essential heavy metals (e.g.,
zinc and manganese) seem to protect against the develop-
ment of AMD. For most trace elements, there are only a
limited number of studies available in the public domain to
date, and further research is required to assess their potential
role as a biomarker or as protective supplement.8. Hormones
In this section, we discuss the few hormones that have been
investigated in relation to AMD: leptin, melatonin, and dehy-
droepiandrosterone sulfate (DHEAS). A complete overview of the
studies and references is provided in Supplementary Table 7.
8.1. Leptin
Because AMD is amultifactorial disease in which dietary factors
and bodymass index also play a role in the disease mechanism,
it has been suggested that the principal hormone involved in
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studies support this theory; both showed a reduction in serum
leptin levels in AMD patients compared with controls.85,306 After
controlling for potential confounders, including smoking, body
mass index, blood pressure, and HDL-C, the association
remained significant, which suggests that mechanisms other
than body fat underlie the relationship between leptin levels and
AMD.306 The third study did not observe a difference in leptin
levels in patients versus control individuals.124
8.2. Melatonin
Melatonin has strong antioxidative capacities, is expressed in
the retina, and expression levels decrease during
aging.173,276,277 Two studies investigated the levels of mela-
tonin in AMD. One showed elevated blood levels of daytime
melatonin in pseudophakic AMD patients.296 The second
study analyzed the major metabolite of melatonin in urine, 6-
sulfatoxymelatonin, and described lower levels in AMD.286
Comparing the 2 studies is difficult because of the differ-
ences inmethodology and fluidmatrix analyzed, so additional
experiments linking melatonin and AMD are necessary.
8.3. Dehydroepiandrosterone sulfate
DHEAS is a sulfate ester of DHEA, which is an endogenous
steroid hormone synthesized from cholesterol in the adrenal
glands and serves as precursor molecule for sex steroids,
androgen and estrogen.212 It has been suggested that DHEAS
has antioxidant effects.212,330,342 In addition, the DHEAS level
in blood decreases with age.23,212,330 Since both oxidative
stress and aging are important risk factors for AMD,59 the
question arises whether DHEAS and AMD could be correlated.
Three studies investigated the association between AMD and
DHEAS, all with different outcomes; higher levels of DHEAS
were reported in women with early AMD,69 another study
described low DHEAS in both dry and neovascular AMD
cases,330 and a third study did not find an association between
nAMD and controls.342
In summary, only a limited amount of studies assessing
hormones in AMD have been performed with inconclusive
results and do not seem to be reliable biomarkers for AMD at
this point in time.9. Factors related to comorbidities
AMD has been suggested to share risk factors or coexist with
other diseases, such as kidney disease, diabetes mellitus, and
Alzheimer’s disease. Factors related to these comorbidities are
discussed in Sections 9.1e9.3, respectively. Although AMDhas
not been associated with liver disease before, some studies
investigated factors related to liver function and these are
described in Section 9.4. A complete overview of the studies
and references is provided in Supplementary Table 8.
9.1. Kidney disease
Several studies have suggested overlapping risk factors be-
tween AMD and kidney diseases.77,189,203,356 A number oflarge, often population-based, studies have not only investi-
gated kidney function, such as glomerular filtration rate, but
also markers that can be measured in serum/plasma like
creatinine and cystatin-C. In the Beaver Dam Eye Study,
serum cystatin-C was associated to the incidence of early
AMD and nAMD.189 In the Multi-Ethnic Study of Atheroscle-
rosis, this association was only found when the highest
deciles of cystatin-C were compared with other deciles with
prevalence of early AMD.51 In the Hatoyama study, no asso-
ciation between cystatin-C and AMD was found.15
Several large studies investigated creatinine in patients,
but no clear association between serum creatinine and AMD
was found. Two reports from the Korean National Health and
Nutrition Examination Survey describe a significant difference
between AMD patients and controls, but after adjustment for
other variables, no significant associationwas found.50,261 The
remainder of the studies, including large population-based
studies such as the Multi-Ethnic Study of Atherosclerosis
and the Singapore Malay Eye Study, did not find
any association between serum creatinine and
AMD.31,33,37,150,152,153,247
Another indicator of renal health is blood urea nitrogen,
but also for this factor, no link was established with
AMD.31,50,189,261
9.2. Diabetes mellitus
Although some cardiovascular risk factors, such as smoking,
have been consistently related to AMD, there are conflicting
results for an association between diabetes mellitus and
AMD.43 Several studies, mostly population-based, measured
glycated hemoglobin and glucose as indicators for the pres-
ence of diabetesmellitus. Only one study found lower levels of
glucose in advanced AMD,199 but none of the other studies
described an association of either markers with
AMD.31,33,37,73,88,143,152,153,160,176,321,371,377 Several studies, all
reports from the Korean National Health and Nutrition
Examination Survey, reported lower glycated hemoglobin
levels in AMD50,143,176,177,199; however, studies from other
cohorts detected no difference.33,37,160,342,380
9.3. Alzheimer’s disease
Similar to AMD, the prevalence of Alzheimer’s disease in-
creases with age. This neurological disorder is characterized by
amyloid plaques in the brain, with the main component being
amyloid beta (Ab).16 In AMD, 2 studies identified Ab as a
component of drusen.12,75 In addition, Ab might trigger activa-
tion of the complement cascade in AMD.159 Several isoforms of
Ab with different amino acid lengths exist; in this section, we
discuss the most common isoforms: Ab1-40 and Ab1-42.
A small, case-control study did not show different levels of
Ab1-42 between controls and either dry or neovascular
AMD247; however, 2 more recent case-control studies showed
significantly higher Ab1-42 peptide levels in AMD pa-
tients.120,124 Also after correction for age, Ab1-42 was signifi-
cantly associated with AMD, and there was a trend toward
increasing levels of Ab with increasing disease severity.120 An
association of AMD with Ab1-40 in these studies was less
clear. A significant upregulation was described in one study in
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ference between nAMD patients and controls.124
9.4. Liver function
So far, to our knowledge, no study has focused specifically on
liver function and AMD. In a few studies, indicators of liver
function have been reported as part of a routine blood
examination with no associations between lactate dehydro-
genase, aspartate transaminase, or alanine transaminase and
AMD.31,50,285
For hepatitis B surface antigen on the other hand, an as-
sociation was described in several Korean studies, a country
where hepatitis B is still endemic.50,261,285 In these studies,
hepatitis B surface antigen carrier status was positively
associated with AMD. Hepatitis B surface antigen has been
detected in subretinal fluid, and it is hypothesized these in-
dividuals are therefore at increased risk for uveoretinal pa-
thology, such as AMD.261,285
In conclusion, despite coexistence and overlapping risk
factors with AMD, biomarkers for kidney disease, diabetes
mellitus, and liver disease discussed here do not seem good
biomarker candidates for AMD. As an exception, Ab could
potentially be a marker of disease progression; however,
larger prospective studies are required to confirm these find-
ings. In addition, also in terms of a potential new drug target,
further evaluation of this biomarker in AMD seems worth-
while, as promising anti-Ab therapies are being developed for
Alzheimer’s disease.1610. Hypothesis-free techniques
In the past decade, many advanced high-throughput omic
technologies have been developed. These technologies enable
us to analyze large numbers of markers at the same time in an
untargeted and unbiased manner. Here, we discuss several
omic technologies in associationwithAMD (Fig. 3): proteomics
(Section 10.1), metabolomics (Section 10.2), and epigenomics
(Section 10.3). Expression of circulatingmicroRNAs can also be
measured using high-throughput techniques; these are
described in Section 10.4.
10.1. Proteomics
The field of proteomic research uses mass spectrometry, or
variations to this technique, to determine the nature of pep-
tides or proteins in various tissues or other biological samples.
The advantage of proteomic research is that it delivers results
that are unbiased by preconceived notions or hypotheses.
Within the field of AMD, proteomics has been used in a
number of investigations, and several have been successful in
showing particular proteomic signatures in plasma, vitreous,
and aqueous humor from AMD patients when compared with
controls.
A small study by Kim and colleagues identified 154 proteins
in aqueous humor of 9 nAMD patients and 8 cataract con-
trols.178 In this study, 7 potential biomarker candidates were
selected for further analysis: ceruloplasmin, PEDF, plasma
protease C1 inhibitor, TGF-b1, clusterin, cathepsin D, andcystatin D. The relative abundances of TGF-b1, plasma pro-
tease C1 inhibitor, ceruloplasmin, and PEDF were shown to be
significantly higher in AMD samples compared with controls.
Another small study, collecting and profiling aqueous humor
of 6 nAMD patients and 6 cataract controls, found 68 proteins
to be differentially expressed.372 Only 9 proteins were identi-
fied in both studies, among which were some that were
related to AMD previously (CCL24 and complement FI),
lipocalin-1 and several members of the crystallin family.
These crystallins, known for their chaperone function, may
also be involved in protein-protein interaction, prevention of
apoptosis, and inhibition of inflammation among others.170
Lipocalin-1 concentrations were quantified using enzyme-
linked immunosorbent assay, and levels were significantly
elevated in the aqueous humor of nAMD patients.
A third small study performed a focused proteomic anal-
ysis on protein members of the ubiquitin pathway.201 Differ-
ence in expression of 6 proteins in aqueous humor of 2 AMD
patients compared with 2 controls was reported. This
included the 26S proteasome non-ATPase regulatory subunit 1
(Rpn2), a protein that is also present in plasma. Rpn2 was
therefore selected as potential AMD biomarker and liquid
chromatography-multiple reaction monitoring mass spec-
trometry of another 15 aqueous humor samples showed a
relative increase of Rpn2 in nAMD patients.
Kang and colleagues analyzed aqueous humor samples of
26 treatment naive patients with nAMD and 18 controls.169 By
comparing expression profiles in exosomes of aqueous humor
and cultured RPE cells, 6 candidate proteins were selected for
verification in an independent sample set by liquid
chromatography-multiple reaction monitoring mass spec-
trometry: actin, myosin-9, heat shock protein 70, cathepsin D,
cytokeratin 8, and cytokeratin 14. Of these, cytokeratin 8
showed the highest area under the curve value (0.929),
suggesting that it is a strong predictor for AMD. Although
cytokeratins were not previously reported in other proteomic
analyses in AMD and might be valuable markers to further
investigate, it is disputable whether they could qualify as
manageable biomarkers. Cytokeratins are abundant contam-
inants in laboratories,209 so careful replication of these
findings in other laboratories is warranted.
One other study investigated in a targeted manner the
involvement of Wnt modulators in aqueous humor and found
that WNT inhibitory factor 1 (WIF-1) and Dickkopf-related
protein 3 (DKK-3) were upregulated in nAMD.260
In a study of 73 nAMD patients and 15 controls, a large set
of proteins were detected in vitreous humor, of which 19 were
upregulated in nAMD patients.194 Bioinformatic analyses
suggested enrichment of the complement and coagulation
cascades, as well as markers involved in arachidonic acid
metabolism. Of the 19 proteins, 5 were randomly selected for
Western blot validation; alpha-1-antitrypsin reached statisti-
cal significance, whereas ApoA1 and transthyretin showed a
nonsignificant increase in AMD. These findings need valida-
tion in a larger sample set.
Nobl and colleagues investigated vitreous samples of 108
nAMD patients and 24 controls, distributed over a discovery
and validation set, and discovered 101 different proteins.243
Using a closed testing procedure, they focused on 4 differen-
tially expressed proteins as candidate AMD biomarkers:
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nAMD compared with controls, except for opticin, which was
reduced. Upregulation of PEDF and PH2D in nAMD was
described previously.178,194 Clusterin and PEDF remained
significantly increased in nAMD after validation and correc-
tion for multiple testing in an independent sample set using
enzyme-linked immunosorbent assay.
There have been limited plasma proteomic studies. Xu and
colleagues found 28 clinically relevant proteins to be altered
in AMD patients (N ¼ 24) compared with healthy volunteers
(N¼ 6),370 but further investigation of these plasma proteins is
necessary to validate these findings. In addition, 2 studies
using proteomic profiling of the same data set identified 3
potential AMD biomarkers: vinculin, phospolipid transfer
protein, and mannan-binding lectin protease-1.175,179 In gen-
eral, proteomics of plasma or serum is a great analytical
challenge due to the dominant fraction of highly abundant
proteins, which have effectively prevented the discovery of
novel proteomic biomarkers in these fluids in the past.
Therefore, improved technologies are needed. Fortunately,
some progress has been made using quantitative shot-gun
proteomics, recently.10810.2. Metabolomics
Metabolomic studies use mass spectrometric technologies or
nuclear magnetic resonance spectroscopy to measure de-
rivatives of metabolism. The technique offers a snapshot of
the physiological state of an organism at the level of body
fluids (urine, tears, serum, and plasma), cells or even tissues.
Metabolomic analysis of AMD has great potential to uncover
novel pathways in the disease that are reflective of the inter-
action between the genetic blueprint of individual and envi-
ronmental factors that influence the metabolites (e.g., diet
and smoking). To date, only one metabolome-wide study was
conducted in plasma samples of 26 nAMD patients and 19
controls. Pathway analysis pointed toward involvement of
tyrosine metabolism, urea metabolism, and vitamin-
Derelated metabolism.25310.3. Epigenomics
Although it is clear that both genetic components as well as
environmental elements contribute to the risk of developing
AMD, it is less clear how these 2 systems interact. This
interaction is the domain of epigenetics, induced changes in
the expression levels of genes controlled by outside in-
fluences. Epigenetics is a broad term, encompassing many
possible regulatory mechanisms of gene expression. One type
of epigenetic mark that has been explored in a number of
studies is the difference inDNAmethylation patterns between
cases and controls.
Epigenetic changes can be observed in peripheral blood
leukocytes, which are relatively easy to obtain. One study
showed a decrease in methylation near the IL17RC promotor
region, suggesting that this could serve as a potential
biomarker for AMD.355 However, the finding could not be
validated by an independent studywith a sufficiently powered
study design.249
Based on these results, and also because epigenetic
mechanisms are likely to be tissue specific, the relationship
between DNA methylation patterns in peripheral blood and
retinal tissue was investigated in a recent study.250 Although
no epigenome-wide association peak was observed, the study
did report consistent methylation changes across multiple
samples near the ARMS2 locus and near the protease serine 50
(PRSS50) gene.
Despite a limited sample size, the results provided some
evidence that methylation patterns in blood leukocytes could
serve as proxies for retinal changes, implying that such
studies could deliver additional biomarkers for AMD.25010.4. Circulating microRNAs
AmicroRNA (miRNA) is a small noncoding RNAmolecule that
regulates gene expression after transcription, thereby influ-
encing biological processes. These miRNAs are present in
circulation and could potentially serve as biomarkers.229
Because we focus on compounds found in body fluids, only
Fig. 4 e Flow diagram of literature search. The screening and selection process of studies included for this review is depicted
in the flow diagram.
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serum or plasma are described here.
In a small study by Ertekin and colleagues,84 plasma sam-
ples of 33 nAMD patients and 31 controls were analyzed for the
expression of 384 miRNAs. They found 16 miRNAs to be
differentially expressed between the 2 groups and additionally
discovered 10 miRNAs to be only expressed in nAMD patients.
Grassmann and colleagues identified 203 cmiRNAs in
serum, of which 3 (hsa-mir-301-3p, hsa-mir-361-5p, and hsa-
mir-424-5p) were significantly altered in nAMD patients
(N ¼ 129) compared with control individuals (N ¼ 147).114 No
significant association was found in GA patients (N ¼ 59),
suggesting different mechanisms for advanced AMD sub-
types. Pathway analysis of the genes that are likely regulated
by the altered cmiRNAs implicated the mTOR and TGF-b
pathways in nAMD and knockdown of these cmiRNAs in vitro
resulted in increased angiogenesis but only significantly for
hsa-mir-361-5p.
Szemraj and colleagues also reported significant differ-
ences in cmiRNA profiles between dry and neovascular AMD
patients.328 In this study, serum expression levels of 377
miRNA genes in 300 AMD patients (150 nAMD/150 dry AMD
patients) and 200 control individuals were analyzed. This
study identified 31 differentially expressed miRNAs between
patients and controls, including 2 of the 3 previously associ-
ated114 cmiRNAs (hsa-mir-301-5p and hsa-mir-424-5p). Of the
differentially expressed miRNAs in this study, 5 were signifi-
cantly different between patients with dry and neovascular
AMD. In addition, the correlation between these miRNAs and
expression of VEGF and VEGFR2 was assessed, and it was
suggested that miRNA Let-7 is implicated in the neoangio-
genesis in nAMD.So far, limited studies on miRNA profiling in AMD have
been performed and results need to be replicated in larger
studies; however, these initial findings emphasize the poten-
tial of cmiRNAs as biomarkers in AMD.
In general, studies using hypothesis-free techniques
demonstrate proof of concept that omic analyses are able to
identify novel biomarkers for AMD; however, more are needed
to validate results and to confirm the clinical utility of these
biomarkers.11. Conclusion and future directions
In summary, numerous compounds have been analyzed in
relation to AMD. However, only a few of these have potential
as AMD biomarkers. The most promising biomarker candi-
dates belong to the oxidative stress pathway, the complement
system, and to a lesser extent, lipid metabolism. Finally, the
use of hypothesis-free techniques in biomarker detection
holds great promise. For summarized findings regarding fac-
tors belonging to the other biological pathways described in
this review, we refer to the closing paragraphs of the respec-
tive chapters. As of yet, none of the biomarkers that we have
reviewed here are used clinically.
Many studies reported decreased antioxidant levels and
elevated levels of oxidized proteins or lipids indicating
oxidative stress in AMD. MDA is often used as a marker for
lipid peroxidation, and increased levels of MDA have been
very consistently observed in both wet and dry AMD (11 of 11
studies, Section 3.1). In addition, most studies reported higher
levels of homocysteine, an intermediate in the oxidative
stress pathway, in AMD (12 of 18 studies, Section 3.3). Besides
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indicate the involvement of the complement system in AMD.
Products of complement activation and levels of complement
activationddescribed by the ratio of C3 and its degradation
product C3d (C3d/C3)dwere repeatedly associated with AMD
(Section 4.1). In addition, there is clear involvement of lipids in
AMD from genetic andmolecular studies; however, the role of
systemic lipids in AMD is not fully elucidated, and therefore,
they are not yet applicable as robust biomarkers for the
disease.
In general, many inconsistencies exist between studies
evaluating biomarkers and their association with AMD. The
contradicting results are difficult to interpret due to a variety
of differences between studies, including methodological
differences (fasting vs nonfasting blood), different
populations (Caucasian/Asian/Mediterranean) with different
dietary habits, different study designs, different analytical
methods, and correction factors, but also types of AMD
included in the studies. It must be noted that compiling and
comparison of data deriving from different sources represent
a major limitation. Therefore, large well-conducted prospec-
tive studies are needed to further clarify these results.
Although AMD represents a phenotype restricted to the
eye, many studies have investigated systemic markers in
relation to AMD; however, because of the presence of the
blood-retinal barrier, biomarkers might be only locally
dysregulated inside the eye without a measurable systemic
effect. In addition, some compounds are differently expressed
between tissues, leading to different results when analyzing
different matrices. One might therefore argue to measure
markers only locally; however, because of the invasive char-
acter and accompanying ethical issues, systemic markers are
preferred for implementation as clinical biomarkers.
Until now, most studies have targeted specific single bio-
markers in a candidate-driven approach. Omic studies with an
unbiased view are heavily outnumbered. Future biomarker
research should therefore combine hypothesis-free as well as
candidate-driven approaches. Quantitative analytical ap-
proaches applied in an untargeted and targeted fashion, such as
metabolomic or proteomic studies, are necessary to identify
novel biomarker candidates. Once validated as robust and reli-
able markers, they can offer more insights into the etiology and
pathogenesis of AMD and support prediction, diagnosis, stratifi-
cation,monitoring of treatment, anddrugdevelopment forAMD.
Other biomarker types in AMD such as genetic factors,
imaging biomarkers, or visual function measurements are
currently of key importance for proper clinical diagnosis,
stratification, and treatment of AMD. In the future, these
established clinical examinations and diagnostic tests may
well be applied in combinationwithmolecular biomarkers, an
area which is still in a nascent stage.12. Methods of literature search
A review of literature was performed through a thorough
PubMed search in November 2015. We used the following
keywords and their synonyms in various combinations: age-
related macular degeneration, serum, plasma, blood, urine,
tear, aqueous, and vitreous. No limitations were set for thetime range covered by our search, and therefore, all articles
published until our search were included.
All abstracts were screened for relevance and full texts of
the selected articles were studied. We included only articles
written in English. Articles cited in the reference lists of articles
obtained through this search were also included whenever
relevant. Animal, ex vivo, and in vitro studies were excluded.
To include the most recent developments before submission,
the search was repeated in June 2016. An overview of our se-
lection process is detailed in Fig. 4.
After the final article selection, all described compounds in
these studies were grouped based on their common biological
function or pathway, and results were discussed accordingly.
Of note, compounds that were only described once in litera-
ture were not mentioned in this review to reduce the effect of
selective reporting.13. Disclosures
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